CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,022,004 | +40.6% | 1,007,512 | +3.3% | 0.00% | +50.0% |
Q2 2023 | $10,680,620 | +484.7% | 975,399 | +365.6% | 0.00% | – |
Q1 2023 | $1,826,639 | +107.7% | 209,477 | +49.3% | 0.00% | – |
Q4 2022 | $879,550 | +78.8% | 140,279 | -0.2% | 0.00% | – |
Q3 2022 | $492,000 | +20.0% | 140,509 | +1.1% | 0.00% | – |
Q2 2022 | $410,000 | -82.0% | 138,989 | -81.0% | 0.00% | – |
Q1 2022 | $2,275,000 | +11.1% | 731,717 | +20.7% | 0.00% | – |
Q4 2021 | $2,048,000 | -8.4% | 606,077 | -1.0% | 0.00% | – |
Q3 2021 | $2,235,000 | -19.7% | 612,482 | -4.0% | 0.00% | – |
Q2 2021 | $2,783,000 | -11.1% | 638,226 | -7.5% | 0.00% | -100.0% |
Q1 2021 | $3,131,000 | -25.3% | 689,634 | -5.5% | 0.00% | 0.0% |
Q4 2020 | $4,189,000 | -22.2% | 729,721 | -1.8% | 0.00% | 0.0% |
Q3 2020 | $5,381,000 | +98.9% | 743,171 | -4.1% | 0.00% | 0.0% |
Q2 2020 | $2,705,000 | +117.4% | 775,144 | -7.8% | 0.00% | – |
Q1 2020 | $1,244,000 | -22.2% | 840,907 | +3.2% | 0.00% | – |
Q4 2019 | $1,598,000 | -62.6% | 815,190 | -2.4% | 0.00% | -100.0% |
Q3 2019 | $4,273,000 | -23.1% | 834,873 | +7.5% | 0.00% | 0.0% |
Q2 2019 | $5,560,000 | -43.4% | 776,570 | +5.1% | 0.00% | -50.0% |
Q1 2019 | $9,815,000 | +76.3% | 739,028 | +4.5% | 0.00% | 0.0% |
Q4 2018 | $5,566,000 | -29.9% | 707,114 | -1.3% | 0.00% | 0.0% |
Q3 2018 | $7,941,000 | -12.9% | 716,627 | +5.5% | 0.00% | 0.0% |
Q2 2018 | $9,115,000 | +516.3% | 679,176 | +496.6% | 0.00% | – |
Q1 2018 | $1,479,000 | +88.9% | 113,849 | +33.7% | 0.00% | – |
Q4 2017 | $783,000 | +10.1% | 85,124 | -3.6% | 0.00% | – |
Q3 2017 | $711,000 | +134.7% | 88,285 | +67.7% | 0.00% | – |
Q2 2017 | $303,000 | +34.1% | 52,632 | 0.0% | 0.00% | – |
Q1 2017 | $226,000 | +318.5% | 52,632 | +69.2% | 0.00% | – |
Q4 2016 | $54,000 | -6.9% | 31,100 | +3.3% | 0.00% | – |
Q3 2016 | $58,000 | +11.5% | 30,116 | 0.0% | 0.00% | – |
Q2 2016 | $52,000 | +26.8% | 30,116 | 0.0% | 0.00% | – |
Q1 2016 | $41,000 | -19.6% | 30,116 | 0.0% | 0.00% | – |
Q4 2015 | $51,000 | -12.1% | 30,116 | 0.0% | 0.00% | – |
Q3 2015 | $58,000 | +45.0% | 30,116 | +101.0% | 0.00% | – |
Q2 2015 | $40,000 | -68.0% | 14,986 | -16.9% | 0.00% | – |
Q1 2015 | $125,000 | -29.4% | 18,024 | 0.0% | 0.00% | – |
Q4 2014 | $177,000 | – | 18,024 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |